Biologic predictors in follicular lymphoma: Importance of markers of immune response

Leukemia and Lymphoma

Volumn 48, Issue 12, 2007, Pages 2403-2411

  Kelley, Todd ^a   Beck, Rose ^a   Absi, Ahmed ^a   Jin, Tao ^a   Pohlman, Brad ^a   Hsi, Eric ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Lymphoma and Hodgkin disease; Manipulation of the immune response; Neoplasia; Prognostication

Indexed keywords

CD68 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; ONCOGENE PROTEIN MUM1; ONCOPROTEIN; PROTEIN BCL 2; RITUXIMAB; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL MATURATION; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOLOGICAL MARKERS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERFERON REGULATORY FACTORS; LYMPHOMA, FOLLICULAR; MACROPHAGES; MALE; MIDDLE AGED; NEPRILYSIN; PROPORTIONAL HAZARDS MODELS;

EID: 37149013899     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701665954     Document Type: Article

References (43)

1. Solal-Celigny, P., Roy, P., Colombat, P., White, J., Armitage, J. O. and Arranz-Saez, R. (2004) Follicular lymphoma international prognostic index. Blood, 104, pp. 1258-1265.
2. Montoto, S., Lopez-Guillermo, A., Altes, A., Perea, G., Ferrer, A. and Camos, M. (2004) Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol, 15, pp. 1484-1489.
3. Martin, A. R., Weisenburger, D. D., Chan, W. C., Ruby, E. I., Anderson, J. R. and Vose, J. M. (1995) Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood, 85, pp. 3671-3678.
4. Hans, C. P., Weisenburger, D. D., Vose, J. M., Hock, L. M., Lynch, J. C. and Aoun, P. (2003) A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood, 101, pp. 2363-2367.
5. Lopez-Guillermo, A., Cabanillas, F., McDonnell, T. I., Mclaughlin, P., Smith, T. and Pugh, W. (1999) Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood, 93, pp. 3081-3087.
6. Weisenburger, D. D., Gascoyne, R. D., Bierman, P. J., Shenkier, T., Horsman, D. E. and Lynch, J. C. (2000) Clinical significance of the t(14;18) and BCL2 overexpression in follicular large cell lymphoma. Leuk Lymphoma, 36, pp. 513-523.
7. Viardot, A., Moller, P., Hogel, J., Werner, K., Mechtersheimer, G. and Ho, A. D. (2002) Clinicopathologic correlations of genomic gains and losses in follicular lymphoma. J Clin Oncol, 20, pp. 4523-4530.
8. Llanos, M., Alvarez-Arguelles, H., Aleman, R., Oramas, J., Diaz-Flores, L. and Batista, N. (2001) Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma. Med Oncol, 18, pp. 15-22.
9. Bilalovic, N., Blystad, A. K., Golouh, R., Nesland, J. M., Selak, I. and Trinh, D. (2004) Expression of bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lymphoma. Am J Clin Pathol, 121, pp. 34-42.
10. Moller, M. B., Nielsen, O. and Pedersen, N. T. (2002) Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma. Histopathology, 41, pp. 322-330.
11. Besa, P. C., McLaughlin, P. W., Cox, J. D. and Fuller, L. M. (1995) Long term assessment of patterns of treatment failure and survival in patients with stage I or II follicular lymphoma. Cancer, 75, pp. 2361-2367.
12. Dave, S. S., Wright, G., Tan, B., Rosenwald, A., Gascoyne, R. D. and Chan, W. C. (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med, 351, pp. 2159-2169.
13. Farinha, P., Masoudi, H., Skinnider, B. F., Shumansky, K., Spinelli, J. J. and Gill, K. (2005) Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood, 106, pp. 2169-2174.
14. Farinha, P., Campo, E., Banham, A., Masoudi, H., Skinnider, B. F. and Connors, J. M. (2006) The architectural pattern of FOXP3+ T-cells is an indpendent predictor of survival in patients with follicular lymphoma. Mod Pathol, 19, p. 1043a.
15. Carreras, J., Lopez-Guillermo, A., Fox, B. C., Colomo, L., Martinez, A. and Roncador, G. (2006) High numbers of tumor infiltrating FOXP3-positive regulatory T-cells are associated with improved overall survival in follicular lymphoma. Blood, 108, pp. 2957-2964.
16. Lee, A. M., Clear, A. J., Calaminici, M., Davies, A. J., Jordan, S. and Macdougall, F. (2006) Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol, 24, pp. 2052-2059.
17. Alvaro, T., Lejeune, M., Salvado, M. T., Lopez, C., Jaen, J. and Bosch, R. (2006) Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol, 24, pp. 5350-5357.
18. Mann, R. B. and Berard, C. W. (1983) Criteria for the cytologic subclassification of follicular lymphomas: A proposed alternative method. Hematol Oncol, 1, pp. 187-192.
19. Jaffe, E. S., Harris, N. L., Stein, H. and Vardiman, J. (2001) Tumours of Haematopoeitic and Lymphoid Tissues.
20. Sup, S. J., Alemany, C. A., Pohlman, B., Elson, P., Malhi, S. and Thakkar, S. (2005) Expression of bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome. J Clin Oncol, 23, pp. 3773-3779.
21. Fisher, R. I., LeBlanc, M., Press, O. W., Maloney, D. G., Unger, J. M. and Miller, T. P. (2005) New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol, 23, pp. 8447-8452.
22. Liu, Q., Fayad, L., Cabanillas, F., Hagemeister, F. B., Ayers, G. D. and Hess, M. (2006) Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol, 24, pp. 1582-1589.
23. Morel, P., Dupriez, B., Plantier-Colcher, I., Gosselin, B., Declercq, C. and Pollet, J. P. (1993) Long-term outcome of follicular low-grade lymphoma. A report of 91 patients. Ann Hematol, 66, pp. 303-308.
24. Aviles, A., Diaz-Maqueo, J. C., Sanchez, E., Cortes, H. D. and Ayala, J. R. (1991) Long-term results in patients with low-grade nodular non-Hodgkin's lymphoma. A randomized trial comparing chemotherapy plus radiotherapy with chemotherapy alone. Acta Oncol, 30, pp. 329-333.
25. Dogan, A., Du, M. Q., Aiello, A., Diss, T. C., Ye, H. T. and Pan, L. X. (1998) Follicular lymphomas contain a clonally linked but phenotypically distinct neoplastic B-cell population in the interfollicular zone. Blood, 91, pp. 4708-4714.
26. Natkunam, Y., Warnke, R. A., Montgomery, K., Falini, B. and van De Rijn, M. (2001) Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol, 14, pp. 686-694.
27. Falini, B., Fizzotti, M., Pucciarini, A., Bigerna, B., Marafioti, T. and Gambacorta, M. (2000) A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood, 95, pp. 2084-2092.
28. Gaidano, G. and Carbone, A. (2000) MUM1: A step ahead toward the understanding of lymphoma histogenesis. Leukemia, 14, pp. 563-566.
29. Naresh, K. N. (2007) MUM1 expression dichotomises follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes. Haematologica, 92, pp. 267-268.
30. Karube, K., Guo, Y., Suzumiya, J., Sugita, Y., Nomura, Y. and Yamamoto, K. (2007) CD10(-)MUM1(+) follicular lymphoma lacks BCL2 translocation and shows characteristic biological and clinical features. Blood, 109, pp. 3076-3079.
31. Hans, C. P., Weisenburger, D. D., Greiner, T. C., Gascoyne, R. D., Delabie, J. and Ott, G. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, pp. 275-282.
32. Poulsen, C. B., Borup, R., Nielsen, F. C., Borregaard, N., Hansen, M. and Gronbaek, K. (2005) Microarray-based classification of diffuse large B-cell lymphoma. Eur J Haematol, 74, pp. 453-465.
33. Chang, C. C., McClintock, S., Cleveland, R. P., Trzpuc, T., Vesole, D. H. and Logan, B. (2004) Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol, 28, pp. 464-470.
34. Chang, C. C., Lorek, J., Sabath, D. E., Li, Y., Chitambar, C. R. and Logan, B. (2002) Expression of MUM1/IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia. Blood, 100, pp. 4671-4675.
35. Uranishi, M., Iida, S., Sanda, T., Ishida, T., Tajima, E. and Ito, M. (2005) Multiple myeloma oncogene 1 (MUM1)/interferon regulatory factor 4 (IRF4) upregulates monokine induced by interferon-γ (MIG) gene expression in B-cell malignancy. Leukemia, 19, pp. 1471-1478.
36. Hori, S. and Sakaguchi, S. (2004) Foxp3: A critical regulator of the development and function of regulatory T cells. Microbes Infect, 6, pp. 745-751.
37. Yang, Z. Z., Novak, A. J., Stenson, M. J., Witzig, T. E. and Ansell, S. M. (2006) Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood, 107, pp. 3639-3646.
38. Ziegler, S. F. (2006) FOXP3: Of mice and men. Annu Rev Immunol, 24, pp. 209-226.
39. Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P. and Mottram, P. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med, 10, pp. 942-949.
40. Wolf, D., Wolf, A. M., Rumpold, H., Fiegl, H., Zeimet, A. G. and Muller-Holzner, E. (2005) The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res, 11, pp. 8326-8331.
41. Yang, Z. Z., Novak, A. J., Ziesmer, S. C., Witzig, T. E. and Ansell, S. M. (2006) Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res, 66, pp. 10145-10152.
42. Alvaro, T., Lejeune, M., Camacho, F. I., Salvado, M. T., Sanchez, L. and Garcia, J. F. (2006) The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica, 91, pp. 1605-1612.
43. Winter, J. N., Weller, E. A., Horning, S. J., Krajewska, M., Variakojis, D. and Habermann, T. M. (2006) Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: A prospective correlative study. Blood, 107, pp. 4207-4213.